KZIA - ノボゲン （Kazia Therapeutics Limited）

Kazia Therapeutics has released its Q223 activity report and provided a business update for the quarter. Q2 was marked by increased preclinical efforts towards exploring the applicability and effic…

Those following along with Kazia Therapeutics Limited ( ASX:KZA ) will no doubt be intrigued by the recent purchase of…

Kazia Therapeutics Ltd (ASX:KZA, NASDAQ:KZIA) CEO Dr James Garner speaks with Proactive after confirming a two-tranche capital raising initiative to raise A$4.5 million through placements to professional and sophisticated investors. The company''s also offer eligible shareholders the opportunity to acquire up to A$30,000 of new shares through a share purchase plan.#ProactiveInvestors #KaziaTherapeutics #asx #pharma #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews Contact Details Proactive Investors Jonathan Jackson +61 413 713 744 Jonathan@proactiveinvestors.com

EQS-News: Kazia Therapeutics Ltd Kazia Therapeutics talks positive pre-clinical data for EVT801 06.12.2022 / 17:45 CET/CEST The issuer is solely responsible for the content of this announcement. C…

EQS-News: Kazia Therapeutics Ltd Kazia Therapeutics talks positive pre-clinical data for EVT801 06.12.2022 / 17:45 CET/CEST The issuer is solely responsible for the content of this announcement. Contact Details Proactive Investors Jonathan Jackson +61 413

Kazia Therapeutics (KZIA) stock rose ~3% on Wednesday after the company provided update on Q1''23 cash flow report and said that it has sufficient cash to last to end CY22.Kazia added…

Kazia Therapeutics'' (ASX:KZA) paxalisib brain cancer drug has demonstrated positive efficacy signals against a range of preclinical models of metastatic melanoma.

Kazia Therapeutics Limited (NASDAQ:KZIA) closed Friday at $1.42 per share, up from $1.39 a day earlier. While Kazia Therapeutics Limited has overperformed by 2.16%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, KZIA fell by -86.73%, with highs and lows ranging from $12.28 to $1.37, whereas […]

Kazia Therapeutics Limited (NASDAQ:KZIA)’s traded shares stood at 0.35 million during the last session, with the company’s beta value hitting 2.22. At the close of trading, the stock’s price was $1.66, to imply a decrease of -11.23% or -$0.21 in intraday trading. The KZIA share’s 52-week high remains $12.28, putting it -639.76% down since that … Kazia Therapeutics Limited (NASDAQ: KZIA) Stock Has Dropped -56.77% Over The Month – Is There Room For Growth? Read More »

Kazia Therapeutics Limited (NASDAQ:KZIA)’s traded shares stood at 0.35 million during the last session, with the company’s beta value hitting 2.22. At the close of trading, the stock’s price was $1.66, to imply a decrease of -11.23% or -$0.21 in intraday trading. The KZIA share’s 52-week high remains $12.28, putting it -639.76% down since that … Kazia Therapeutics Limited (NASDAQ: KZIA) Stock Has Dropped -56.77% Over The Month – Is There Room For Growth? Read More »

LONDON, UK / ACCESSWIRE / August 8, 2022 / Kazia Therapeutics has reported that the company’s lead asset paxalisib (PI3K/mTOR inhibitor) has not graduated to Stage 2 of the Phase III GBM AGILE study in glioblastoma multiforme (GBM), as advised by the study sponsors (Global Coalition for Adaptive Research, GCAR). The study is still fully… Read More »Kazia Therapeutics (KZIA): Ambiguity in GBM But Pipeline Still Busy

Oncology-focused drug developer Kazia Therapeutics (ASX: KZA) has presented promising new data from an ongoing phase one clinical trial of its lead drug paxalisib in combination with radiotherapy for the treatment of brain metastases. Interim data from the first stage of the study, led by Dr Jonathan Yang at the Memorial Sloan Kettering Cancer Centre […] The post Kazia Therapeutics reveals 100% response rate in interim data from brain metastases drug trial appeared first on Small Caps .

Kazia Therapeutics (KZIA) is trading 53% higher before the bell after the company reported positive data from a phase I trial of its drug, paxalisib, in combination with radiotherapy…

SYDNEY, Aug. 5, 2022 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce the presentation of promising new dat…